Abstract
Interim Positron-Emission Tomography (int-PET) and the peripheral blood absolute lymphocyte/monocyte ratio at di- agnosis (ALC/AMC-DX) have been shown to be predictors for progression-free survival (PFS) and time to progression (TTP) in classical Hodgkin lymphoma (cHL). Therefore, we studied if the combination of ALC/AMC-DX and the (int-PET) can further stratified PFS and TTP in cHL patients. Patients were required to be diagnosed, treated, and followed with int-PET at Mayo Clinic, Rochester, Minnesota. From 2000 until 2008, 111 cHL patients qualified for the study. The median follow-up was 2.8 years (range: 0.3 - 10.4 years). Patients with a negative int-PET (N = 98) pre- sented with a higher ALC/AMC-DX (median of 2.32, range: 0.26 - 37.5) compared with patients with a positive int-PET (N = 13) (median of 0.9, range: 0.29 - 3.10), p 1.1. Group 1 experienced superior PFS and TTP in comparison with the other groups. In conclusion, the combination of ALC/AMC-DX and the int-PET provides a simple model to assess clinical outcomes in cHL.
Highlights
The peripheral blood absolute lymphocyte/monocyte ratio at diagnosis (ALC/absolute monocyte count (AMC)-DX), as a surrogate biomarker of host immunity (i.e., absolute lymphocyte count (ALC)) and tumor microenvironment (i.e., AMC), has been recently reported to be a predictor for overall survival, lymphoma-specific survival, progression-free survival, and time to progression in classical Hodgkin lymphoma [1,2]
We studied if the combination of ALC/AMC-DX and the can further stratified progression-free survival (PFS) and time to progression (TTP) in classical Hodgkin lymphoma (cHL) patients
We studied if the ALC/AMC-DX is an independent predictor in comparison with the Interim Positron-Emission Tomography (int-PET) for PFS and TTP and if the combination of ALC/AMC-DX and the intPET can further stratified the clinical outcomes of PFS and TTP in patients with cHL
Summary
The peripheral blood absolute lymphocyte/monocyte ratio at diagnosis (ALC/AMC-DX), as a surrogate biomarker of host immunity (i.e., ALC) and tumor microenvironment (i.e., AMC), has been recently reported to be a predictor for overall survival, lymphoma-specific survival, progression-free survival, and time to progression in classical Hodgkin lymphoma (cHL) [1,2]. Interim PositronEmission Tomography (int-PET), as a functional imaging test for tumor activity, has been shown to be a predictor for progression-free survival (PFS) and time to progression (TTP) in cHL [3]. Romano et al [4] reported that even though the ALC/AMC ratio correlated with prognosis, the int-PET was better discriminator of survival than the ALC/AMC ratio. In an attempt to validate Romano’s findings, we studied if the ALC/AMC-DX is an independent predictor in comparison with the int-PET for PFS and TTP and if the combination of ALC/AMC-DX and the intPET can further stratified the clinical outcomes of PFS and TTP in patients with cHL
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
